GENE ONLINE|News &
Opinion
Blog

2018-03-06|

6 March, 2014: First time Scientist gene-editing Immune Cells Successful, open a new treatment possibility for AIDS

by GeneOnline
Share To

A research team from the Perelman School of Medicine, University of Pennsylvania, enrolled 12 patients in an uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells. The patients had the chronic aviremic HIV infection while they were receiving highly active antiretroviral therapy. After the infusion of 10 billion autologous CD4 T cells, the blood level of HIV DNA decreased in most patients. This study was a milestone for gene-editing technology application on fatal disease treatment.

Reference
http://www.nejm.org/doi/full/10.1056/NEJMoa1300662

Image Source
https://en.wikipedia.org/wiki/HIV

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
ASCO Breakthrough 2024: Radiation Alone Works as Well as Chemoradiation for Low-Risk Nasopharyngeal Cancer
2024-08-08
New Research Highlights Potential for Surgery-Free Management of Esophageal Cancer at ASCO Breakthrough 2024
2024-08-08
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
LATEST
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
EVENT
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top